Study on Application of Electronic Healthcare Records in Pharmacovigilance in US and EU

Abstract

Abstract: Objective To provide thought and references for the promotion of ADR monitoring in China. Methods Study on the current state and the practical application by using of data from electronic healthcare records for pharmacovigilance. The shortcomings were summarized and analyzed, suggestions on improving ADR monitoring and post-marketing clinical studies were put forward based on HIS. Results &Conclusion It can get data from the real world to carry out the ADR monitoring by using the HIS, improving the quality of ADR reporting at source and reducing the omission.To strengthen active surveillance can make up for the inadequacy of spontaneous reporting. It is a good way to improve the quality and the value of ADR monitoring. We should draw lessons from foreign advanced experience and technology, strengthen the HIS construction and information comprehensive utilization.

Key words: adverse drug reaction, electronic healthcare records, pharmacovigilance, hospital information system

CLC Number:

R994.11

WANG Ling. Study on Application of Electronic Healthcare Records in Pharmacovigilance in US and EU[J]. Chinese Journal of Pharmacovigilance, 2015, 12(3): 156-159.

References

[1] CFDA.药品不良反应报告和监测管理办法（卫生部令第81号）[EB/OL].（2011-05-04）[2014-06-23]. http://www.sda.gov.cn/WS01/CL0053/62621.html.
[2] 王玲，周晶鑫，张学宁，等.药品不良反应报告数据规整的实践与思考[J].中国药物警戒，2014，11（7）：407-412.
[3] Robb M A,Racoosin J A,Sherman R,et al.The US Food and Drug Administration's Sentinel Initiative:Expanding the horizons of medical product safety [J].Pharmacoepidemiology and Drug Safety, 2012,21（S1）：9-11.
[4] 周晓枫，刘青，蔡兵，等.全球上市后药品主动监测系统概况[J].药物流行病学杂志，2012,21（7）：338-342.
[5] Stang P E,Ryan P B,Racoosin J A,et al. Advancing the science for active surveillance:rationale and design for the Observational Medical Outcomes Partnershop[J]. Annals of Internal Medicine, 2010,153（9）:600-606.
[6] 蔡兵，刘青，周晓枫，等.药品安全主动监测方法简介[J].药物流行病学杂志，2013,22（8）：439-443.
[7] Takahashi Y,Nishida Y,Asai S. Utilization of health care databases for Pharmacoepidemiology[J].Eur J Clin Pharmacol, 2012,68（2）:123-129.
[8] Michael D Murray.Use of Data from Electronic Health Records for pharmacoepidemiology[J].Curr Epidemiol Rep，2014，1:186-193.
[9] Hennessy S.Use of health care databases in pharmacoepidemiology[J].Basic & Clinical Pharmacology & Toxicology，2006,98,311-313.
[10] FDA.Prescription Drug User Fee Act(PDUFA) IV Drug Safety Five Year Plan[EB/OL].（2010-06）[2014-12-23].www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm-
216354.pdf.
[11] 杜丽君.英国国民医疗保健体制下全科医疗模式探析与启示[J].中国农村卫生事业管理，2014，34（10）：1225-1227.
[12] 苏雅茄，张新炯，胡小莹，等.用于药物警戒研究的自动化医疗保健数据库简介[J].药物流行病学杂志，2011,20（10）：536-540.
[13] Louise Wood,Carlos Martinez.The general practice research database:role in pharmacovigilance[J].Drug Safety，2004，27(12):871-881.
[14] Rachel A. Charlton，John G. Weil，Marianne C. Cunnington，et al.Identifying Major Congenital Malformations in the UK General Practice Research Database (GPRD)[J]. Drug Saf，2010，33(9): 741-750.
[15] C.Cooper，M.Steinbuch，R.Stevenson，et al. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK[J].Osteoporos Int，2010，21（4）:569-577.
[16] Eelko Hak，Bianca Mulder，Catharina C. M. Schuiling-Veninga，et al. Use of Acid-Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Crossover Study using the General Practice Research Database[J]. Drug Saf，2013，36（11）:1097-1104.
[17] FDA. FDA's Sentinel Initiative-Background[EB/OL].（2010-01-19）[2014-12-23].http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm.
[18] Yu-Lin Huang，Jinhee Moon，Jodi B Segal. A Comparison of Active Adverse Event Surveillance Systems Worldwide[J]. Drug Saf，2014，37（8）:581-596.
[19] Jose Luis Oliveira,Pedro Lopes,Tiago Nunes，et al. The EU-ADR Web Platform:delivering advanced pharmacovigilance tools[J].Pharmacoepidemiology and drug safety,2013,22(5): 459-467.
[20] Xiaofeng Zhou， Sundaresan Murugesan，Harshvinder Bhullar，et al. An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance[J]. Drug Saf，2013， 36（2）:119-134.
[21] Elizabeth B Andrews，Andrea V Margulis，Patricia Tennis，et al. Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases[J]. Curr Epidemiol Rep，2014，1:194-205.
[22] 王玲，黄玲. 药品不良反应报告数据共享平台的建设及对风险沟通的思考[J].中国药物警戒，2014，11（9）:536-541.
[23] 中华人民共和国国务院.国务院关于印发卫生事业发展“十二五”规划的通知（国发〔2012〕57号）[EB/OL].（2012-10-08）[2014-12-23].http://www.gov.cn/zwgk/2012-10/19/content_2246908.htm.